Women's health company Evofem Biosciences Inc (OTCID: EVFM) disclosed on Monday that it has entered into an exclusive distribution agreement with pharmaceutical distributor Clovis Davis Pharmaceuticals, LLC to commercialise SOLOSEC (secnidazole) 2g oral granules across sub-Saharan Africa, extending the product's global reach.

Under the agreement, Clovis Davis will lead distribution, marketing and sales of SOLOSEC, a single-dose oral treatment approved by the US Food and Drug Administration for bacterial vaginosis and trichomoniasis in patients aged 12 and older. Regulatory filings across the region will be based on Evofem Biosciences' existing FDA-approved dossier.

The company highlighted significant market potential, noting bacterial vaginosis affects an estimated 25% of women in sub-Saharan Africa, while trichomoniasis remains widespread, with approximately one-third of global new infections occurring in the WHO African region.

Evofem Biosciences said the partnership supports its strategy to expand access to women's health treatments in underserved markets, leveraging Clovis Davis Pharmaceuticals' distribution capabilities to drive adoption across the region.